Crossmark

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Crossref DOI link: https://doi.org/10.1038/s41375-021-01131-6

Published Online: 2021-02-08

Published Print: 2021-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patkar, Nikhil https://orcid.org/0000-0001-9234-2857
Kakirde, Chinmayee

Shaikh, Anam Fatima

Salve, Rakhi

Bhanshe, Prasanna

Chatterjee, Gaurav

Rajpal, Sweta

Joshi, Swapnali

Chaudhary, Shruti

Kodgule, Rohan

Ghoghale, Sitaram

Deshpande, Nilesh

Shetty, Dhanalaxmi

Khizer, Syed Hasan

Jain, Hasmukh

Bagal, Bhausaheb

Menon, Hari

Khattry, Navin https://orcid.org/0000-0001-5708-6472
Sengar, Manju

Tembhare, Prashant https://orcid.org/0000-0002-9030-0415
Subramanian, Papagudi https://orcid.org/0000-0001-9107-5937
Gujral, Sumeet
Funding

Funding for this research was provided by:

DBT India Alliance (IA/CPHI/14/1/501485)
License Information

Text and Data Mining valid from 2021-02-08

Version of Record valid from 2021-02-08
More Information

Article History

Received: 26 August 2020

Revised: 30 November 2020

Accepted: 7 January 2021

First Online: 8 February 2021

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below